4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $38.56.

Several brokerages have recently commented on FDMT. Morgan Stanley reduced their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a research report on Monday, January 13th. Chardan Capital reiterated a "buy" rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Bank of America lowered their price objective on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, January 13th.

4D Molecular Therapeutics Stock Down 4.3 %

FDMT traded down $0.21 during trading on Friday, reaching $4.66. The stock had a trading volume of 343,091 shares, compared to its average volume of 697,403. The business has a 50-day moving average of $6.31 and a 200-day moving average of $10.91. 4D Molecular Therapeutics has a one year low of $4.43 and a one year high of $36.25.

Institutional Trading of 4D Molecular Therapeutics

Several large investors have recently modified their holdings of FDMT. Healthcare of Ontario Pension Plan Trust Fund raised its position in 4D Molecular Therapeutics by 10.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company's stock valued at $14,819,000 after purchasing an additional 65,000 shares during the last quarter. Barclays PLC raised its holdings in shares of 4D Molecular Therapeutics by 141.0% during the third quarter. Barclays PLC now owns 114,848 shares of the company's stock valued at $1,241,000 after acquiring an additional 67,202 shares in the last quarter. Novo Holdings A S lifted its stake in 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company's stock worth $16,215,000 after acquiring an additional 100,000 shares during the period. nVerses Capital LLC bought a new stake in 4D Molecular Therapeutics in the third quarter valued at $40,000. Finally, Braidwell LP boosted its holdings in 4D Molecular Therapeutics by 231.7% in the third quarter. Braidwell LP now owns 1,225,448 shares of the company's stock valued at $13,247,000 after acquiring an additional 855,990 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.